Camurus Logo

Camurus

Develops and commercializes long-acting medicines for severe and chronic diseases.

CAMX | ST

Overview

Corporate Details

ISIN(s):
SE0007692850 (+2 more)
LEI:
5493003S6Z6VI7WYFQ06
Country:
Sweden
Address:
Ideon Science Park, 223 70 Lund

Description

Camurus is a science-led biopharmaceutical company that develops and commercializes innovative, long-acting medicines for severe and chronic diseases. The company specializes in advanced drug delivery systems designed to improve treatment outcomes, enhance patient quality of life, and provide value to society. Its therapeutic focus areas include opioid dependence, cancer and supportive care, endocrine conditions, rare diseases, and disorders of the central nervous system. Camurus maintains a diversified research and development pipeline to address significant unmet medical needs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 07:00
Change in number of shares and votes in Camurus
English 159.5 KB
2025-11-28 07:00
Förändring av antalet aktier och röster i Camurus
Swedish 157.0 KB
2025-11-13 07:00
Valberedning utsedd inför Camurus årsstämma 2026
Swedish 149.2 KB
2025-11-13 07:00
Camurus’ Nomination Committee appointed for the Annual General Meeting 2026
English 151.9 KB
2025-11-10 08:00
Camurus reports positive topline results for CAM2056, semaglutide monthly depot
English 213.9 KB
2025-11-10 08:00
Camurus rapporterar positiva resultat för CAM2056, semaglutid månadsdepå
Swedish 188.3 KB
2025-11-06 07:00 Swedish 1.0 MB
2025-11-06 07:00 English 857.9 KB
2025-09-30 07:00
Förändring av antalet aktier och röster i Camurus
Swedish 134.6 KB
2025-09-30 07:00
Change in number of shares and votes in Camurus
English 136.1 KB
2025-07-17 07:00 Swedish 923.9 KB
2025-07-17 07:00 English 916.2 KB
2025-07-01 11:30
Camurus’ Oczyesa® receives marketing authorization for treatment of acromegaly …
English 184.9 KB
2025-07-01 11:30
Camurus meddelar EU-godkännande av Oczyesa® för behandling av akromegali
Swedish 182.4 KB
2025-06-30 07:00
Förändring av antalet aktier och röster i Camurus
Swedish 130.6 KB

Automate Your Workflow. Get a real-time feed of all Camurus filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Camurus

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Camurus via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-07-17 Torsten Malmström Other Sell 10,000 6,806,400.00 SEK
2024-06-17 Jon Uguzne Garay Alonso Other Other 33,750 N/A
2024-05-14 Torsten Malmström Other Sell 1,495 844,675.00 SEK
2024-05-10 Annette Mattsson Other Sell 1,000 550,000.00 SEK
2023-12-15 Annette Mattsson Other Other 1,000 169,500.00 SEK
2023-09-18 Annette Mattsson Other Sell 1,000 294,600.00 SEK
2023-09-06 Maria Lundqvist Other Other 381 N/A
2023-08-23 Maria Lundqvist Other Sell 77 22,610.28 SEK
2023-08-23 Maria Lundqvist Other Sell 58 17,032.86 SEK
2023-08-23 Maria Lundqvist Other Other 77 13,051.50 SEK

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.